The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $5.07

Today's change-0.27 -5.06%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.
 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $5.07

Today's change-0.27 -5.06%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

ARIAD Pharmaceuticals Inc crosses below 20-day moving average

ARIAD Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$0.27 or 5.06% to (U.S.)$5.07 and crossing below its 20-day moving average. Over the last five days, shares have gained 1.00%, but are down 18.88% for the last year to date. Shares have underperformed the S&P 500 by 17.57% during the last year.

Key company metrics

  • Open(U.S.) $5.30
  • Previous close(U.S.) $5.34
  • High(U.S.) $5.30
  • Low(U.S.) $5.06
  • Bid / Ask-- / --
  • YTD % change-18.88%
  • Volume3,654,117
  • Average volume (10-day)3,656,574
  • Average volume (1-month)3,760,935
  • Average volume (3-month)3,574,687
  • 52-week range(U.S.) $4.72 to (U.S.) $10.07
  • Beta1.67
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.94
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-118.71%

Although this company's net profit margin is negative, it is above the industry average and implies that ARIAD Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue29292467
Total other revenue--------
Total revenue29292467
Gross profit29292366
Total cost of revenue0011
Total operating expense85887474
Selling / general / administrative37493440
Research & development48393933
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-56-59-50-7
Interest income (expense), net non-operating-5-4-4-4
Gain (loss) on sale of assets--------
Other--------
Income before tax-61-63-52-6
Income after tax-55-63-53-6
Income tax, total-6000
Net income-55-63-53-6
Total adjustments to net income--------
Net income before extra. items-55-63-53-6
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-55-63-53-6
Inc. avail. to common incl. extra. items-55-63-53-6
Diluted net income-55-63-53-6
Dilution adjustment0------
Diluted weighted average shares189189188187
Diluted EPS excluding extraordinary itemsvalue per share-0.29-0.33-0.28-0.03
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.29-0.33-0.28-0.03